Gensaic develops next-generation metabolic medicines by decoding the language of therapeutic delivery to target tissues and organelles. The FORGE™ platform uses AI-enabled generative protein design and billion-scale evolution to create delivery vehicles with enhanced selectivity and potency. This technology focuses on engineering precise intracellular delivery mechanisms for novel treatments across various metabolic indications.
Funding
$13.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug delivery systems often lack precision, leading to inefficient targeting and limited effectiveness of therapeutic payloads at the tissue, cell, and subcellular levels. This inefficiency can result in increased dosages, off-target effects, and reduced therapeutic outcomes.
Solution
Gensaic develops multi-functional proteins designed for precise therapeutic delivery using generative protein modeling and in-vivo protein evolution. Their technology aims to enhance the targeting capabilities of therapeutic payloads, enabling delivery across tissues, cells, and even subcellular compartments. By decoding the language of dimensional delivery, Gensaic seeks to improve the effectiveness and reduce the side effects associated with traditional drug delivery methods. The company leverages unbiased discovery and generative protein design to create proteins tailored for specific delivery requirements.
Target Audience
Gensaic's primary customers are pharmaceutical companies and research institutions focused on developing targeted therapies and improving drug delivery methods.
Features
- Generative protein modeling for designing novel delivery proteins.
- In-vivo protein evolution to optimize protein function and targeting.
- Multi-functional protein engineering for enhanced therapeutic payload delivery.
- Targeted delivery at tissue, cell, and subcellular levels.